Differential regulation of platelet inhibition by cGMP- and cAMP-dependent protein kinases by unknown
POSTER PRESENTATION Open Access
Differential regulation of platelet inhibition by
cGMP- and cAMP-dependent protein kinases
Hariharan Subramanian1, Ulrich Walter2, Stepan Gambaryan1,3*
From 6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Erfurt, Germany. 28-30 June 2013
Background
Under normal conditions circulating platelets are main-
tained in a resting state by the paracrine signaling mole-
cules, prostacyclin (PGI2) and nitric oxide (NO), released
from vascular endothelial cells. PGI2 and NO trigger the
synthesis of cAMP and cGMP, respectively, which in turn
leads to the activation of Protein Kinase A (PKA) and Pro-
tein Kinase G (PKG). These cyclic nucleotide-dependent
protein kinases phosphorylate numerous substrate pro-
teins involved in several aspects of platelet activation.
Both, PKA and PKG can phosphorylate the same sub-
strates including VASP, LASP, RAP1GAP2, Rap1B,
HSP27, and some others. Only few substrates are known
to be specific for PKA (PDE3) and PKG (PDE5) [1,2].
Here we report the identification and characterization of a
new PKA specific substrate, CalDAG-GEFI (calcium and
diacylglycerol regulated guanine nucleotide exchange fac-
tor I), a guanine exchange factor for Rap1b in platelets.
Results
Using radioactive phosphate incorporation assay, we
identified S587 as the major PKA phosphorylation site in
CalDAG-GEFI, which was confirmed by mass spectrome-
try. In platelets, PKA stimulation leads to strong phos-
phorylation of CalDAG-GEFI and inhibition of Rap1b
activation triggered by thrombin, as well as calcium iono-
phore, which indicates a potential role of CalDAG-GEFI
phosphorylation in the inhibition of Rap1b activation.
However, PKG activation did not significantly phosphor-
ylate CalDAG-GEFI, and inhibits thrombin-stimulated
Rap1b by inhibition of calcium mobilization but did not
inhibit calcium ionophore-triggered Rap1b activation. In
HEK293 cells transfected with CalDAG-GEFI, calcium
ionophore triggered Rap1b activation and forskolin sti-
mulated PKA phosphorylation of CalDAG-GEFI leads to
inhibition of Rap1b activation. But in cells with S587A
mutant, PKA activation did not inhibit Rap1b activation.
The phospho-mimetic (S587D) mutant failed to activate
Rap1b following calcium ionophore stimulation.
Conclusion
These results confirmed that PKA phosphorylation of
CalDAG-GEFI inhibits Rap1b activation. We propose
that this is one of the important mechanisms of platelet
inhibition mediated by cAMP/PKA signaling. Presented
data show that PKA and PKG could utilize similar and/or
diverse intracellular mechanisms involved in platelet
inhibitory pathways.
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